News Report: On November 28th, Youcare Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Youcare Pharmaceutical") released an announcement regarding the voluntary disclosure of its subsidiary YKYY018 nebulizer inhalation agent obtaining FDA approval for clinical trials.

The announcement indicates that the wholly-owned subsidiary of Youcare Pharmaceutical, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Youcare Kechuang"), recently received a notification from the U.S. Food and Drug Administration (hereinafter referred to as "FDA") regarding the approval for the clinical trial of YKYY018 nebulized inhalation agent for the prevention and treatment of respiratory syncytial virus (RSV) infection (Study May Proceed Letter, IND number: 178457).

The announcement indicates that respiratory syncytial virus (RSV) is a ubiquitous and contagious enveloped RNA virus that can cause respiratory diseases, particularly affecting susceptible groups such as children, the elderly, and individuals with compromised immune systems. As of now, there are no approved RSV infection treatment drugs available globally, and there is a significant and urgent unmet need in the clinical treatment field.

YKYY018 Nebulized Inhalation Agent is an internationally original membrane fusion inhibitor drug independently developed by Youcare Science & Technology based on its full-process AI platform. It is used for the prevention and treatment of RSV infection.

https://finance.eastmoney.com/a/202511303578468589.html